Evolus (NASDAQ:EOLS) Stock Price Up 15.3% – What’s Next?

Shares of Evolus, Inc. (NASDAQ:EOLS) were up 15.3% during mid-day trading on Thursday . The stock traded as high as $14.85 and last traded at $16.44. Approximately 203,784 shares traded hands during trading, a decline of 77% from the average daily volume of 868,460 shares. The stock had previously closed at $14.26.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on EOLS shares. Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Evolus in a research note on Tuesday, January 21st. Barclays increased their target price on Evolus from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Monday, January 27th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price target on shares of Evolus in a research report on Wednesday, January 22nd.

Evolus Stock Performance

The company has a market capitalization of $952.33 million, a PE ratio of -16.53 and a beta of 1.33. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The business’s fifty day moving average is $11.99 and its two-hundred day moving average is $13.95.

Institutional Investors Weigh In On Evolus

Several institutional investors have recently modified their holdings of EOLS. KBC Group NV purchased a new stake in shares of Evolus during the 4th quarter valued at about $49,000. IFP Advisors Inc lifted its position in Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after purchasing an additional 4,709 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Evolus in the fourth quarter worth approximately $106,000. Quantbot Technologies LP purchased a new stake in Evolus in the fourth quarter worth approximately $118,000. Finally, Point72 Asset Management L.P. bought a new stake in Evolus in the 3rd quarter worth approximately $132,000. 90.69% of the stock is owned by hedge funds and other institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.